Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Advanced antibody production services for exceptional IVD assays

Medix Biochemica, producer of monoclonal antibodies for the global IVD industry and diagnostic rapid tests, is presenting its MedixMAB™ by Design and MedixMAB™ Manufacturing antibody production services to the European market at MEDICA 2013, Dusseldorf, Germany, 20-23 November, Hall 3, Stand F44.

With 30 years of antibody expertise, Medix offers customised services for the in vitro generation of high-performance recombinant or monoclonal antibodies and Fab fragments for superior IVD assays. With all antibodies produced to the strictest international quality standards (ISO 9001, ISO 13485 and FDA QSR) the services equip manufacturers with a competitive advantage, helping to increase sales revenue without the need to invest in costly production facilities and expertise.

The advanced phage display recombinant production technology of the MedixMAB by Design service enables the targeting of a broader range of antigens than possible in vivo, including poorly immunoreactive and toxic compounds, with production available on a range of scales (mg-kg). As a rapid alternative to producing full length monoclonal antibodies, Fab fragments can be generated in just three months, and greatly enhance specificity and sensitivity of IVD assays in solid-phase applications.

MedixMAB Manufacturing presents a cost-effective and flexible monoclonal antibody outsourcing option for IVD manufacturers. Completely tailored to the needs of the project, the service offers the option to outsource all or just parts of the manufacturing process to the scale and deadlines required. Medix Biochemica offers a secure and stable contract manufacturing option, and is a trusted partner for the world’s leading IVD manufacturers.

All the MedixMAB services come with a personal project manager assigned to each project, providing full consultation and support throughout the process, tailoring the services to each individual need.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy